Journal
BRITISH JOURNAL OF PHARMACOLOGY
Volume 154, Issue 6, Pages 1163-1165Publisher
WILEY
DOI: 10.1038/bjp.2008.233
Keywords
kinin B-1 receptor; bradykinin B-2 receptor; inflammatory bowel disease
Categories
Ask authors/readers for more resources
A surprising proportion of patients with inflammatory bowel disease (IBD) remain refractory to all classes of drugs presently in clinical use. Kinins are inflammatory mediators of potential relevance in IBD, because at least the kinin B-1 receptor subtype is upregulated in human or animal intestinal inflammation and also both B-1 and B-2 receptors for kinins support inflammation and epithelial electrogenic ion transport that leads to secretory diarrhoea. In this issue of the BJP, Hara et al. report the therapeutic effect of a modern and selective nonpeptide kinin B-1 receptor antagonist, SSR240612 ((2R)-2-(((3R)-3-(1,3-benzodioxol- 5-yl)-3-(((6-methoxy-2-naphthyl)sulphonyl)amino)propanoyl)amino)-3-(4-((2R,6S)-2,6-dimethylpiperidinyl)methyl)phenyl)N-isopropyl- N-methylpropanamide hydrochloride), with benefits such as decreased neutrophil influx and improved macroscopic tissue scoring. The results were corroborated using kinin B-1 receptor gene-knockout mice. Further, kinin B-1 receptor upregulation in this inflammatory model is partially dependent on TNF-alpha, a recognized target for IBD pharmacotherapy. More work is warranted to evaluate the value of the kinin B-1 receptor antagonists as a novel anti-inflammatory therapeutic option for IBD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available